Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #40

Submission information
Submission Number: 40
Submission ID: 148323
Submission UUID: beae2b78-e81e-4bc7-ab77-d84f8942320c

Created: Thu, 08/07/2025 - 10:37
Completed: Thu, 08/07/2025 - 10:47
Changed: Thu, 08/07/2025 - 10:47

Remote IP address: 10.208.28.64
Submitted by: Anonymous
Language: English

Is draft: No
Abstract Title: Optimized Syngeneic Neuroblastoma Models to Advance Cell Therapies
Abstract: Adoptive cell therapies, including T and natural killer T (NKT) cells expressing GD2 specific chimeric antigen receptors (CAR), have shown promise in treating relapsed/refractory (r/r) neuroblastoma (NB) but remain non-curative. A significant barrier to improving these therapies is the reliance on xenogeneic models, which fail to capture the full spectrum of innate and adaptive immune responses. We recently reported that CAR NKTs have superior in vivo antitumor activity in several syngeneic tumor models (PMID: 39354225), but not in NB due to the lack of relevant models.

To develop syngeneic NB models for evaluating CAR T and CAR NKT cell therapies, murine NB cell lines expressing GD2 and B7H3 were created via lentiviral transduction and optimized through orthotopic implantation into C57BL/6 mice. These cell lines were engineered for cyclophosphamide (Cy) resistance to model r/r NB and support lymphodepleting preconditioning. The tumor microenvironment (TME) was characterized using flow cytometry. Murine T and NKT cells were transduced with GD2/B7H3 CARs encoding CD28 or 41BB costimulatory domains.

Results showed that GD2 and B7H3 NB models exhibited high tumor inoculation rates and stable antigen expression. The TME featured diverse immune populations. In vitro, CAR T/NKTs eliminated antigen-specific NB cells. In vivo, both therapies reduced tumor burden post Cy preconditioning, mirroring clinical trial outcomes but without achieving complete tumor control.

To conclude, we developed Cy resistant syngeneic orthotopic NB models with stable GD2 and B7H3 expression. These models enable a detailed study of cell therapies in the context of an intact immune system and TME.
Abstract:
Authors:
  1. First Name: Ying
    Last Name: Wang
    Organization: Baylor College of Medicine
  2. First Name: Linjie
    Last Name: Guo
    Degree(s): M.D. Ph.D.
    Organization: Baylor College of Medicine
  3. First Name: Akshaya
    Last Name: Adaikkalavan
    Organization: Baylor College of Medicine
  4. First Name: Amy
    Middle Initial: N.
    Last Name: Courtney
    Degree(s): Ph.D.
    Organization: Baylor College of Medicine
  5. First Name: Xavier
    Last Name: Rios
    Degree(s): M.D. Ph.D.
    Organization: Baylor College of Medicine
  6. First Name: Xin
    Last Name: Xu
    Degree(s): Ph.D.
    Organization: Baylor College of Medicine
  7. First Name: Michael
    Middle Initial: S.
    Last Name: Wood
    Organization: Baylor College of Medicine
  8. First Name: Erica
    Middle Initial: Di
    Last Name: Pierro
    Degree(s): Ph.D.
    Organization: Baylor College of Medicine
  9. First Name: Xin
    Last Name: Zhou
    Degree(s): Ph.D.
    Organization: University of North Carolina at Chapel Hill
  10. First Name: Gianpietro
    Last Name: Dotti
    Degree(s): M.D.
    Organization: University of North Carolina at Chapel Hill
  11. First Name: Leonid
    Middle Initial: S.
    Last Name: Metelitsa
    Degree(s): M.D. Ph.D.
    Organization: Baylor College of Medicine
Presenting Author: Ying Wang
Institution: Baylor College of Medicine
Email Address: ying.wang3@bcm.edu